The Human Evidence on Senolytics

This story is part of The Longevity Marketplace, our seven-part guide. Start with the full guide.

Building on the picture of senescent cells from earlier in this series, the foundational mouse experiments demonstrated that selective removal of senescent cells could delay aspects of age-related decline and improve function in disease models. Those results created a legitimate scientific rationale for testing senolytic agents in people. The human evidence that has accumulated since is more limited and more cautious than the commercial narrative usually acknowledges.

As of mid-2026, no senolytic agent has received regulatory approval for an aging or senescence-related indication. The published human data consist primarily of small pilot studies, open-label feasibility trials, and a smaller number of randomized controlled trials. Most have focused on safety, tolerability, and biomarker changes rather than definitive clinical benefit.

The Core Human Data: Dasatinib Plus Quercetin

The combination of dasatinib and quercetin (D+Q) remains the most studied systemic senolytic regimen in humans. The doses used in the key early trials were typically intermittent: for example, 100 mg of dasatinib plus 1,000 to 1,250 mg of quercetin given for two or three consecutive days, followed by a rest period, and repeated over weeks or months.

One of the earliest and most cited human signals came from a small open-label study in nine individuals with diabetic kidney disease. A short course of D+Q reduced markers of senescent cell burden in adipose tissue and lowered certain circulating SASP-related factors. The study was open-label and small, but it provided direct tissue evidence that the combination could engage its intended target in living humans.

Subsequent work examined D+Q in idiopathic pulmonary fibrosis, a progressive lung disease in which senescence is thought to play a role. Early open-label trials established feasibility and tolerability of intermittent dosing, and a separate randomized pilot followed in 2023. Signals on physical function appeared in some reports, but the studies were not powered to demonstrate definitive clinical efficacy, and larger confirmatory work remains needed.

Alzheimer’s disease and related cognitive impairment have also been explored. Pilot studies, including SToMP-AD and related efforts, tested intermittent D+Q in older adults with or at risk for Alzheimer’s. Safety and central nervous system penetration of dasatinib were assessed. SToMP-AD, with five patients, found some changes in spinal fluid markers but no significant change in cognition or brain imaging. A separate 12-person pilot, reported by Millar and colleagues in EBioMedicine in 2025, found a small gain on a cognitive screening test only among those with the lowest starting scores. Certainty of evidence remains low. Larger randomized trials are underway or planned.

A 2024 randomized trial in postmenopausal women, roughly sixty participants, tested intermittent D+Q over about twenty weeks with a bone resorption marker as the primary endpoint. The combination did not lower bone resorption overall, though a bone formation marker rose transiently in secondary analyses. The trial illustrated both the feasibility of longer intermittent regimens and the difficulty of showing strong functional or structural benefit in relatively healthy older adults.

Other Agents and Approaches

Fisetin, another flavonoid with senolytic activity in preclinical models, has entered human testing, including trials focused on osteoarthritis and other indications. Published clinical data remain more limited than for D+Q.

More targeted approaches, including BCL-xL inhibitors delivered locally (for example in the eye for diabetic macular edema), produced early mixed readouts. In a 2025 phase 2b trial, Unity Biotechnology’s eye drug UBX1325 missed its main goal: it did not prove as good as the standard drug aflibercept averaged over weeks 20 and 24, though it did at week 36, and Unity’s stockholders later voted to dissolve the company. Local delivery reduces systemic exposure and may improve the therapeutic index for certain indications, but it does not address systemic senescent cell burden.

Next-generation strategies, more selective senolytics, senomorphics that suppress the SASP without killing cells, and even early exploration of cell-based or nanoparticle approaches, are in various stages of preclinical or early clinical development. None have yet produced the kind of large, definitive outcome trials that would support broad clinical use for aging.

What the Evidence Does and Does Not Show

The human data support several limited conclusions. Intermittent D+Q can reduce senescent cell markers in some tissues. The regimen appears generally tolerable in the short term in the populations studied, with adverse events that are often mild or consistent with the known profiles of the individual agents. Some trials have reported improvements in selected biomarkers or exploratory functional measures.

The data do not yet support the stronger claims that circulate in commercial contexts. There is no strong, replicated evidence that systemic senolytic treatment reliably improves major clinical outcomes, hard endpoints such as disease progression, disability, mortality, or sustained gains in physical or cognitive function, across adequately powered randomized trials. Most studies remain small. Many lack placebo controls or long-term follow-up. Certainty of evidence for clinical benefit is rated low to very low in recent systematic assessments.

This is the normal state of an early translational field. Proof-of-biology and safety signals come first. Efficacy on meaningful endpoints requires larger, longer, better-controlled trials. Those trials take time and resources. The commercial marketplace does not wait for them.

Implications for Interpretation

When a product or clinic claims that a senolytic approach will clear “zombie cells” and thereby improve aging, the claim should be measured against the actual human evidence base summarized above. Target engagement in small studies is not the same as proven clinical benefit. Intermittent prescription-level regimens tested under medical supervision are not the same as daily consumer supplements. The distance between those categories is the subject of the next part of this series.

Correction, Sept. 24, 2026: An earlier version of this article said a 2025 phase 2b trial of a senolytic eye drug reported more encouraging results. That trial, Unity Biotechnology’s ASPIRE study of UBX1325, missed its main goal: it did not show the drug was as good as the standard drug aflibercept averaged over weeks 20 and 24, though it did at week 36, according to Unity’s May 5, 2025 announcement. Unity’s stockholders approved dissolving the company on Sept. 18, 2025, according to its SEC filing. The earlier version also said pilot studies had reported preliminary cognitive signals in subgroups without saying which. SToMP-AD, a five-patient trial published by Gonzales et al. in Nature Medicine in 2023, found no significant change in cognition or brain imaging; the subgroup signal came from a separate 12-person pilot published by Millar et al. in EBioMedicine in 2025. It also listed the SToMP-AD paper as Nature Medicine 2025 with a link to an unrelated article; the citation and link have been fixed.

Built against current standards generation: E.G. v4.16 · I.R.G. v1.13 · L.R.G. v1.9 · P.L.G. v1.10. As of August 2026.

Editor written. AI used for spelling and grammar only.